Advanced or Metastatic Solid Tumors with KRAS Mutations or Amplifications research hub

A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

This study is testing a new drug for people with advanced or spread cancers that have a specific genetic change called KRAS. It's the first time this drug is being given to humans, to check its safety, how it works in the body, and if it can help fight the cancer.